Clinical Trial Update: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Velcade (bortezomib) in combination with rituximab for relapsed/refractory mantle cell lymphoma and follicular non-Hodgkin lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-05-20